Trans Genic Inc operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Trans Genic Inc with three other
companies in this sector in Japan:
Medinet Co., Ltd.
sales of 1.70 billion Japanese Yen [US$15.90 million]
of which 100%
was cell processing),
GNI Group Limited
(2.65 billion Japanese Yen [US$24.71 million]
of which 72%
was Medicine Business), and
Japan Tissue Engineering Company Limited
(2.14 billion Japanese Yen [US$19.92 million]
of which 96%
was Regenerative Medicine Products Business).
During the year ended March of 2017, sales at
Trans Genic Inc were ¥2.30 billion (US$21.49 million).
a very small
increase of 0.6%
versus 2016, when the company's sales were ¥2.29 billion.
This was the fifth consecutive year of sales increases at Trans Genic Inc
(and since 2012, sales have increased a total of 279%).
Sales of Genomics Business saw an increase
that was more than double the company's growth rate: sales were up
7.5% in 2017, from
¥390.89 million to ¥420.15 million.
Trans Genic Inc also saw significant increases in sales in
Cro Business (up 4.7% to ¥1.14 billion)
Not all segments of Trans Genic Inc experienced an increase in sales in 2017:
sales of Eliminations and Corporate fell 86.8% to ¥1.65 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
Trans Genic Inc also experienced decreases in sales in
Pathological Diagnosis Business (down 3.5% to ¥399.29 million)
Antibody Reagent Business (down 11.1% to ¥340.60 million)